唾液细胞外微小RNA用于食管癌早期检测与预后判断的临床研究
研究从唾液细胞外囊泡和颗粒中建立6个微小RNA组成的特征谱,并在训练队列(n=342)及内部(n=207)、外部(n=226)验证队列中评估其早期检测食管鳞状细胞癌和预后判断的能力,显示该特征谱可准确识别早期及全期患者,并可预测高风险病例的不良生存。
要点
- 唾液细胞外囊泡和颗粒来源的6个微小RNA特征谱可非侵入性检测早期食管鳞状细胞癌。
- 训练队列中早期(Ⅰ/Ⅱ期)患者检测AUROC=0.969,敏感度92.00%,特异度89.17%。
- 内部验证敏感度90.32%、特异度91.04%;外部验证敏感度91.07%、特异度88.06%。
核心结论
- 基于唾液细胞外囊泡和颗粒的6个微小RNA特征谱可作为食管鳞状细胞癌早期检测和风险分层的非侵入性生物标志物。
研究设计与样本
- 先在预试验队列(n=54)中用微阵列分析唾液细胞外囊泡和颗粒的微小RNA表达谱。
- 用受试者工作特征曲线下面积和最小绝对收缩与选择算子回归分析筛选区分食管鳞状细胞癌患者与对照的微小RNA。
- 用定量逆转录聚合酶链反应在发现队列(n=72)和细胞系中检测候选微小RNA。
- 预测模型在训练队列(n=342)中建立,并在内部验证队列(n=207)和外部验证队列(n=226)中验证。
主要发现
- 微阵列分析鉴定出7个可区分食管鳞状细胞癌患者与对照的微小RNA。
- 因其中1个在发现队列和细胞系中不总能检出,其余6个微小RNA组成检测组合。
- 该组合特征谱在训练队列中准确识别全期食管鳞状细胞癌患者,AUROC=0.968,并在2个独立队列中成功验证。
- 该特征谱在训练队列中区分早期(Ⅰ/Ⅱ期)食管鳞状细胞癌与对照的AUROC=0.969,敏感度=92.00%,特异度=89.17%。
- 内部验证队列敏感度=90.32%、特异度=91.04%;外部验证队列敏感度=91.07%、特异度=88.06%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Early detection of esophageal squamous cell carcinoma (ESCC) will facilitate curative treatment. We aimed to establish a microRNA (miRNA) signature derived from salivary extracellular vesicles and particles (EVPs) for early ESCC detection and prognostication. METHODS: Salivary EVP miRNA expression was profiled in a pilot cohort (n = 54) using microarray. Area under the receiver operator characteristic curve (AUROC) and least absolute shrinkage and selector operation regression analyses were used to prioritize miRNAs that discriminated patients with ESCC from controls. Using quantitative reverse transcription polymerase chain reaction, the candidates were measured in a discovery cohort (n = 72) and cell lines. The prediction models for the biomarkers were derived from a training cohort (n = 342) and validated in an internal cohort (n = 207) and an external cohort (n = 226). RESULTS: The microarray analysis identified 7 miRNAs for distinguishing patients with ESCC from control subjects. Because 1 was not always detectable in the discovery cohort and cell lines, the other 6 miRNAs formed a panel. A signature of this panel accurately identified patients with all-stage ESCC in the training cohort (AUROC = 0.968) and was successfully validated in 2 independent cohorts. Importantly, this signature could distinguish patients with early-stage (stage Ⅰ/Ⅱ) ESCC from control subjects in the training cohort (AUROC = 0.969, sensitivity = 92.00%, specificity = 89.17%) and internal (sensitivity = 90.32%, specificity = 91.04%) and external (sensitivity = 91.07%, specificity = 88.06%) validation cohorts. Moreover, a prognostic signature based on the panel was established and efficiently predicted the high-risk cases with poor progression-free survival and overall survival. CONCLUSIONS: The salivary EVP-based 6-miRNA signature can serve as noninvasive biomarkers for early detection and risk stratification of ESCC. Chinese Clinical Trial Registry, ChiCTR2000031507.
引用
- Li K, Lin Y, Zhou Y, et al. Salivary Extracellular MicroRNAs for Early Detection and Prognostication of Esophageal Cancer: A Clinical Study. Gastroenterology. 2023. PMID: 37399999. doi:10.1053/j.gastro.2023.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。